<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="275">
  <stage>Registered</stage>
  <submitdate>24/08/2005</submitdate>
  <approvaldate>2/09/2005</approvaldate>
  <actrnumber>ACTRN12605000284662</actrnumber>
  <trial_identification>
    <studytitle>A prospective observational study of the effect of a pre-operative 12 week very low calorie diet (VLCD) on liver volume and intra-abdominal fat mass in severely obese patients presenting for obesity surgery.</studytitle>
    <scientifictitle>A prospective observational study of the effect of a pre-operative 12 week very low calorie diet (VLCD) on liver volume and intra-abdominal fat mass in severely obese patients presenting for obesity surgery.</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Fatty liver</healthcondition>
    <conditioncode>
      <conditioncode1>Diet and nutrition</conditioncode1>
      <conditioncode2>Obesity</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Surgery</conditioncode1>
      <conditioncode2>Other surgery</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>40 consecutive consenting patients presenting for obesity surgery will undergo a 12 week preoperative program of weight loss using a VLCD (Optifast) . An abdominal CT scan will be taken at baseline to measure liver volume and intraabdominal fat mass at baseline and a repeat CT scan will be taken at completion of the 12-week VLCD. Ten subjects who are noted to have larger livers on initial CT scan will be invited to undergo 5 serial MRI scans-baseline, 2-weeks, 4-weeks, 8-weeks and 12-weeks in order to assess the pattern of liver size reduction during intervention. Changes in pre-existing obesity related comorbidities, biochemistry and health related quality of life as well as patient acceptability and compliance to the 12-week VLCD will also examined.</interventions>
    <comparator>no control group</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change in liver volume</outcome>
      <timepoint>At 12 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change in intra-abdominal fat</outcome>
      <timepoint>At 12 weeks.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Changes in liver enzymes</outcome>
      <timepoint>At 12 weeks.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in weight</outcome>
      <timepoint>At 12 weeks.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in biochemistry</outcome>
      <timepoint>At 12 weeks.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of life</outcome>
      <timepoint>At 12 weeks.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Comorbidity of obesity</outcome>
      <timepoint>At 12 weeks.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Have body weight less than 150kg and stable within Â±5kg over the previous 3 months, have a pre-operative body mass index greater than 50kg/m2 for women or greater than 40kg/m2 for men or of lower BMI if they fulfill the criteria for a diagnosis of the metabolic syndrome by having 3 or more of the following: waist circumference women &gt;88cm, men&gt;102cm, serum triglycerides&gt;1.69mmol/L, HDL-cholesterol women &lt;1.29mmol/L, men&lt;1.04mmol/L, blood pressure &gt;130/85,FBG&gt;6.1mmol/L, be able to understand and agree to comply with the requirements of the VLCD and monitoring over the 12 weeks, be able to provide informed consent to participate in the study. </inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>60</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Medical contra-indications for use of a VLCD (based on the Optifast VLCD treatment protocol, May 2003) which include: pancreatitis, severe hepatic disease, advancing renal disease, pregnancy and lactation, acute cerebrovascular or cardiovascular disease, overt psychosis, type 1 diabetes, porphyria, inability to complete the 12-week VLCD program and monitoring requirements, inability to understand the requirements for optimal effectiveness of VLCD.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Natural history</purposeobs>
    <duration>Longitudinal</duration>
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/07/2004</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>40</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up complete</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Centre for Obesity Research and Education (CORE)</primarysponsorname>
    <primarysponsoraddress>Monash Medical School
Commercial Road
Melbourne 3004</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Centre for Obesity Research and Education (CORE) Monash University</fundingname>
      <fundingaddress>Monash Medical School
Commercial Road Melbourne 3004</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Novartis</fundingname>
      <fundingaddress>327 -333 Police Rd
Mulgrave VIC 3170</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>none</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication>Colles SL, Dixon JB, Marks P, Strauss BJ, O'Brien P E. Preoperative weight loss with a very-low-energy diet: quantitation of changes in liver and abdominal fat by serial imaging. Am J Clin Nutr 2006;84:304-11.</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>The Avenue Hospital</ethicname>
      <ethicaddress>Melbourne</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Assoc. Prof John Dixon</name>
      <address>Monash University
School of Primary Health Care
Building 1, 270 Ferntree Gully Road
Notting Hill 3168</address>
      <phone>+61 3 9501 2431</phone>
      <fax>+61 3 8575 2233</fax>
      <email>john.dixon@med.monash.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Ms Susan Colles</name>
      <address>Centre for Obesity Research and Education (CORE)
Monash University Medical School
Alfred Hospital
Commercial Road
Melbourne VIC 3004</address>
      <phone>+61 3 99030721</phone>
      <fax>+61 3 95103365</fax>
      <email>susan.colles@med.monash.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Mrs Maureen Dixon</name>
      <address>Monash University
School of Primary Health Care
Building 1, 270 Ferntree Gully Road
Notting Hill 3168</address>
      <phone>+61 3 8575 2273</phone>
      <fax>+61 3 8575 2233</fax>
      <email>maureen.dixon @med.monash.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>